keyword
MENU ▼
Read by QxMD icon Read
search

docetaxel outcome

keyword
https://www.readbyqxmd.com/read/28727517/comparative-toxicity-and-effectiveness-of-trastuzumab-based-chemotherapy-regimens-in-older-women-with-early-stage-breast-cancer
#1
Katherine E Reeder-Hayes, Anne Marie Meyer, Sharon Peacock Hinton, Ke Meng, Lisa A Carey, Stacie B Dusetzina
Purpose The combination of chemotherapy and trastuzumab is the standard of care for adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer. Two regimens have been widely adopted in the United States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH). No head-to-head comparison of these regimens has been conducted in a clinical trial, and existing trial data have limited generalizability to older patients. Methods We used SEER-Medicare data from 2005 to 2013 to compare outcomes of ACTH versus TCH among patients age older than 65 years...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28723519/individual-patient-data-analysis-of-randomized-clinical-trials-impact-of-black-race-on-castration-resistant-prostate-cancer-outcomes
#2
Daniel E Spratt, Yu-Wei Chen, Brandon A Mahal, Joseph R Osborne, Shuang G Zhao, Todd M Morgan, Ganesh Palapattu, Felix Y Feng, Paul L Nguyen
BACKGROUND: Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. OBJECTIVE: To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723476/charting-recent-progress-and-challenges-in-metastatic-castration-resistant-prostate-cancer-is-there-an-optimal-treatment-sequence
#3
REVIEW
Stéphane Oudard, Pablo Maroto, Gaston Demonty, Winald R Gerritsen
CONTEXT: Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. OBJECTIVE: To review and assess treatment options and sequence in patients with mCRPC. EVIDENCE ACQUISITION: To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015...
October 2016: European Urology Focus
https://www.readbyqxmd.com/read/28718092/no-significant-impact-of-prior-treatment-profile-with-docetaxel-on-the-efficacy-of-cabazitaxel-in-japanese-patients-with-metastatic-castration-resistant-prostate-cancer
#4
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
The objective of this study was to retrospectively analyze the oncological outcomes of Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel. This study included a total of 63 consecutive Japanese mCRPC patients treated with cabazitaxel following the failure of docetaxel, and assessed the prognostic significance of cabazitaxel therapy in these patients focusing on the association of efficacies between two taxane agents. After treatment with cabazitaxel (median 5 cycles), prostate-specific antigen (PSA) decline was observed in 39 patients (61...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28702806/efficacy-and-safety-of-nintedanib-plus-docetaxel-in-patients-with-advanced-lung-adenocarcinoma-complementary-and-exploratory-analyses-of-the-phase-iii-lume-lung-1-study
#5
Maya Gottfried, Jaafar Bennouna, Igor Bondarenko, Jean-Yves Douillard, David F Heigener, Maciej Krzakowski, Anders Mellemgaard, Silvia Novello, Sergei Orlov, Yvonne Summers, Joachim von Pawel, Julia Stöhr, Rolf Kaiser, Martin Reck
BACKGROUND: Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) <9 months. OBJECTIVE: This study sought to extend analyses from the LUME-Lung 1 study, specifically for adenocarcinoma patients, to explore the impact of clinically relevant characteristics on outcomes such as time to progression after FLT...
July 12, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28695300/new-fty720-docetaxel-nanoparticle-therapy-overcomes-fty720-induced-lymphopenia-and-inhibits-metastatic-breast-tumour-growth
#6
Heba Alshaker, Qi Wang, Shyam Srivats, Yimin Chao, Colin Cooper, Dmitri Pchejetski
PURPOSE: Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs its use in cancer patients. In this study, we developed a nanoparticle (NP) combining docetaxel (DTX) and FTY for enhanced anticancer effect, targeted tumour delivery and reduced systemic toxicity...
July 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28688700/a-phase-i-study-of-cabazitaxel-in-combination-with-platinum-and-5-fluorouracil-pf-in-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-la-scchn
#7
Nadia Camille, John Rozehnal, Elizabeth Roy, Dariusz Uczkowski, Ashely Olson, Eric Genden, Marita Teng, Richard Bakst, Vishal Gupta, Marshall Posner, Krzysztof Misiukiewicz
BACKGROUND: There is a clinical need to improve outcomes for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), especially in Human Papilloma Virus (HPV) negative and HPV positive subtypes with a significant history of tobacco use. In animal models bearing SCCHN, Cabazitaxel showed an excellent response rate compared to docetaxel and might prove useful in treatment of patients. The primary objective of this study was to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of cabazitaxel when combined with cisplatin and 5-fluorouracil (PF) in induction chemotherapy (IC) for patients with SCCHN...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28674765/improved-survival-for-sequentially-as-opposed-to-concurrently-delivered-neoadjuvant-chemotherapy-in-non-metastatic-breast-cancer
#8
B E P J Vriens, I J H Vriens, M J B Aarts, S M van Gastel, F W P J van den Berkmortel, T J Smilde, L J C van Warmerdam, D J van Spronsen, P G M Peer, M de Boer, V C G Tjan-Heijnen
PURPOSE: The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients. METHODS: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy consisting of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600-T 100 mg/m(2)) or six cycles of TAC as triplet chemotherapy (75/50/500 mg/m(2)) every 3 weeks...
July 3, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28673362/clinical-outcomes-of-retrograde-intra-arterial-chemotherapy-concurrent-with-radiotherapy-for-elderly-oral-squamous-cell-carcinoma-patients-aged-over-80%C3%A2-years-old
#9
Yuichiro Hayashi, Kenji Mitsudo, Kaname Sakuma, Masaki Iida, Toshinori Iwai, Hideyuki Nakashima, Yoshiyuki Okamoto, Toshiyuki Koizumi, Senri Oguri, Makoto Hirota, Mitomu Kioi, Izumi Koike, Masaharu Hata, Iwai Tohnai
BACKGROUND: The aim of this retrospective observational study was to evaluate toxicities, overall survival, and locoregional control in elderly oral squamous cell carcinoma patients who had undergone retrograde intra-arterial chemotherapy combined with radiotherapy. METHODS: Thirty-one elderly patients over 80 years old with oral squamous cell carcinoma were enrolled in present study. The treatment schedule consisted of intra- arterial chemotherapy (docetaxel, total 60 mg/m(2); cisplatin, total 150 mg/m(2)) and daily concurrent radiotherapy (total, 60 Gy) for 6 weeks...
July 3, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28667456/from-clinical-trials-to-clinical-practice-outcome-of-nsabp-b27-neoadjuvant-chemotherapy-regimen-for-high-risk-early-stage-breast-cancer
#10
Hikmat Abdel-Razeq, Lina Marei, Salwa S Saadeh, Hazem Abdulelah, Mahmoud Abu-Nasser, Mourad Salam, Walid Daana, Basel Al-Haj Ali, Ayat Taqash
PURPOSE: Majority of Jordanian breast cancer patients present at a relatively young age and with locally advanced disease highlight the importance of neoadjuvant chemotherapy. This study evaluated the efficacy and safety of NSABP-B27 regimen in high-risk patients in daily clinical practice. METHODS: Patients' medical records and hospital database were searched for all consecutive patients treated at our institution for breast cancer using neoadjuvant NSABP-B27 chemotherapy regimen...
June 30, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28666920/neoadjuvant-therapy-for-triple-negative-and-her2-positive-early-breast-cancer
#11
Nadia Harbeck, Oleg Gluz
Today, neoadjuvant therapy can be considered a therapy standard in triple negative (TNBC) and in HER2-positive (HER2+) (particularly in HER2+ HR-) early breast cancer (EBC). Patients with a pathological complete response (pCR) will have a very favorable outcome. In TNBC, chemotherapy with anthracyclines and taxanes is standard. Data regarding addition of bevacizumab are rather heterogeneous. Addition of carboplatin improves pCR rates independent of BRCA status; whether this will translate into a survival benefit is still unclear...
June 27, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28664431/investigation-of-operative-outcomes-of-thoracoscopic-esophagectomy-after-triplet-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-for-advanced-esophageal-squamous-cell-carcinoma
#12
Yuji Akiyama, Takeshi Iwaya, Fumitaka Endo, Takehiro Chiba, Takeshi Takahara, Koki Otsuka, Hiroyuki Nitta, Keisuke Koeda, Masaru Mizuno, Yusuke Kimura, Akira Sasaki
BACKGROUND: Preoperative chemotherapy with cisplatin and 5-fluorouracil (CF) has become the standard treatment for resectable stage II/III thoracic esophageal carcinoma in Japan. Recently, preoperative triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) has been reported to be effective for locally advanced esophageal cancer. Thoracoscopic esophagectomy (TE) has been increasingly accepted worldwide for the treatment of esophageal cancer. We conducted a retrospective study to evaluate the safety and outcomes of TE after DCF therapy for patients with advanced esophageal cancer...
June 29, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28663235/immunotherapy-of-prostate-cancer-facts-and-hopes
#13
Marijo Bilusic, Ravi A Madan, James L Gulley
In the last few years immunotherapy has become an important cancer treatment modality and while the principles of immunotherapy evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiation therapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity...
June 29, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28661759/adjuvant-cyclophosphamide-and-docetaxel-with-or-without-epirubicin-for-early-top2a-normal-breast-cancer-dbcg-07-read-an-open-label-phase-iii-randomized-trial
#14
Bent Ejlertsen, Malgorzata K Tuxen, Erik Hugger Jakobsen, Maj-Britt Jensen, Ann Soegaard Knoop, Inger Højris, Marianne Ewertz, Eva Balslev, Hella Danø, Peter Michael Vestlev, Julia Kenholm, Dorte L Nielsen, Troels Bechmann, Michael Andersson, Søren Cold, Hanne Melgaard Nielsen, Else Maae, Dorte Carlsen, Henning T Mouridsen
Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 weeks (DC) or three cycles of epirubicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2)) followed by three cycles of docetaxel (100 mg/m(2); EC-D)...
June 29, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28651929/nivolumab-versus-standard-single-agent-therapy-of-investigator-s-choice-in-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-checkmate-141-health-related-quality-of-life-results-from-a-randomised-phase-3-trial
#15
Kevin J Harrington, Robert L Ferris, George Blumenschein, A Dimitrios Colevas, Jérôme Fayette, Lisa Licitra, Stefan Kasper, Caroline Even, Everett E Vokes, Francis Worden, Nabil F Saba, Naomi Kiyota, Robert Haddad, Makoto Tahara, Viktor Grünwald, James W Shaw, Manish Monga, Mark Lynch, Fiona Taylor, Michael DeRosa, Laura Morrissey, Kim Cocks, Maura L Gillison, Joël Guigay
BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs). METHODS: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progressed within 6 months after platinum-based chemotherapy...
June 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28651338/evaluation-of-the-impact-of-tumor-hpv-status-on-outcome-in-patients-with-locally-advanced-unresectable-head-and-neck-squamous-cell-carcinoma-hnscc-receiving-cisplatin-5-fluorouracil-with-or-without-docetaxel-a-subset-analysis-of-eortc-24971-study
#16
A Psyrri, C Fortpied, G Koutsodontis, M Avgeris, C Kroupis, N Goutas, J Menis, L Herman, L Giurgea, E Remenar, M Degardin, I S Pateras, J A Langendijk, C van Herpen, A Awada, J R Germà-Lluch, H R Kienzer, L Licitra, J B Vermorken
Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF over PF, in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable HNSCC. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(-) patients (pts) benefit from adding docetaxel to PF, in which case de-intensifying induction treatment in HPV(+) pts could be considered. Methods: Pre-therapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and qPCR...
June 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28649702/dose-considerations-for-anti-cancer-drugs-in-metastatic-prostate-cancer
#17
REVIEW
Megan Crumbaker, Howard Gurney
Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug-specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses...
June 26, 2017: Prostate
https://www.readbyqxmd.com/read/28633409/the-effect-of-pd-l1-testing-on-the-cost-effectiveness-and-economic-impact-of-immune-checkpoint-inhibitors-for-the-second-line-treatment-of-nsclc
#18
P N Aguiar, L Perry, J Penny-Dimr, H Babiker, H Tadokoro, R A de Mello, G L Lopes
Background: Immune checkpoint inhibitors improve outcomes compared to chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use of PD-L1 testing for patient selection. Design: We developed a decision-analytic model to determine the cost-effectiveness of PD-L1 assessment and second-line immunotherapy versus docetaxel...
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28625638/development-of-psoriatic-arthritis-during-nivolumab-therapy-for-metastatic-non-small-cell-lung-cancer-clinical-outcome-analysis-and-review-of-the-literature
#19
Juan Ruiz-Bañobre, Eva Pérez-Pampín, Jorge García-González, Antonio Gómez-Caamaño, Francisco Javier Barón-Duarte, Rafael López-López, Francisca Vázquez-Rivera
Lung cancer is the leading cause of cancer-related death worldwide. The most common type, non-small cell lung cancer (NSCLC), is further divided into two main types, squamous cell and non-squamous cell (which includes adenocarcinoma). Nivolumab, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has shown not only an overall survival advantage when compared to docetaxel, but also a relatively good side-effect profile among patients with previously treated advanced squamous and non-squamous NSCLC...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28620903/emerging-categories-of-disease-in-advanced-prostate-cancer-and-their-therapeutic-implications
#20
REVIEW
Rahul R Aggarwal, Felix Y Feng, Eric J Small
The treatment of advanced prostate cancer has changed significantly in the last decade, as a result of the introduction of multiple new systemic therapies that have had a positive impact on treatment outcomes. The increasing number of therapies, along with new insights into the biological underpinnings of prostate cancer, have led to a growing appreciation for the heterogeneity of the disease and an awareness of emerging subcategories that have direct therapeutic implications for the practicing clinician. In the metastatic hormone-naive setting, the extent of metastatic disease visible on scans can serve as a useful measure to guide treatment decisions; the addition of docetaxel chemotherapy to hormonal therapy has significant benefit in patients whose scans show more extensive disease...
June 15, 2017: Oncology (Williston Park, NY)
keyword
keyword
58392
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"